First Trust Expanded Technology ETF (ARCA: XPND)

First Trust Expanded Technology ETF (ARCA:XPND), Trade Ideas

First Trust Expanded Technology ETF

Self-storage center real estate investment trusts (REITs) are companies that specialize in owning and operating income-generating storage facilities, commonly known as self-storage centers. Self-store center REITs invest in properties where individuals and businesses can rent space to store their belongings, such as furniture, household items, business inventory, and vehicles of all types.
Investors in self-storage center REITs benefit from the income generated through leasing storage units to tenants. The demand for self-storage has been driven by various factors, including residential moves, downsizing, and businesses seeking additional space.
If you're interested in investing in a self-storage REIT, here are two you could buy today.
<h2 class="wp-block-heading">Don't Miss:</h2>
<ul>
<li>Investing in real estate just got a whole lot simpler. This <a href="https://www.benzinga.com/go/bezos-landlord">Jeff Bezos-backed startup will allow you to become a landlord</a> in just 10 minutes, and you only need $100.</li>
<li>Want To Grow Your Wealth Passively? Unlock Real Wealth with <a href="https://www.benzinga.com/money/cityfunds-yield">Cityfunds&#8217; Exclusive 8% Yield Fund</a>.</li>
</ul>
<h2 class="wp-block-heading">CubeSmart</h2>
CubeSmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CUBE#NYSE">CUBE</a>) is the third largest owner and operator of self-storage facilities in the United States with a portfolio of <a href="https://s201.q4cdn.com/604002580/files/doc_presentations/2024/Mar/04/cube-ir-presentation-march-2024-final.pdf">1,406 properties</a> across 178 markets in 41 states and the District of Columbia.
CubeSmart currently pays a quarterly dividend of $0.51 per share, equating to an annualized dividend of $2.04 per share, which gives its stock a yield of about 4.9% at the time of this writing.
In addition to sporting a high yield, CubeSmart is a dividend-growth superstar. Its <a href="https://investors.cubesmart.com/news--events/news-details/2023/CubeSmart-Announces-4.1-Increase-in-Quarterly-Common-Dividend/default.aspx">4.1% hike in December</a> marked the 14th consecutive year in which it has raised its annual dividend payment.
<h2 class="wp-block-heading">Trending:</h2>
<ul>
<li>Want to Create a Passive Income Stream? <a href="https://www.benzinga.com/go/grow-wealth-passively">These High-Yield Real Estate Notes Might Be Your Holy Grail</a></li>
</ul>
<h2 class="wp-block-heading">National Storage Affiliates Trust</h2>
National Storage Affiliates Trust (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NSA#NYSE">NSA</a>) is a leading owner and operator of self-storage facilities in the U.S. with ownership interests in <a href="https://d1io3yog0oux5.cloudfront.net/_7cb5f849447bdcf18d510090a08d741e/nationalstorageaffiliates/db/226/5086/pdf/NSA+Presentation_March+Update+2024_FINAL.pdf">1,050 properties</a> containing approximately 68.6 million rentable square feet across 42 states and Puerto Rico.
National Storage currently pays a quarterly dividend of $0.56 per share, equating to an annualized dividend of $2.24 per share, which gives its stock a yield of about 6.3% at the time of this writing.&nbsp;
Like CubeSmart, National Storage is a dividend-growth superstar. It has raised its annual dividend payment every year since its initial public offering in 2015, putting it on track for 2024 to mark the ninth consecutive year with an increase.
<h2 class="wp-block-heading">Read Next:</h2>
<ul>
<li>Elon Musk Is Bullish On Austin. Here&#8217;s <a href="https://www.benzinga.com/go/musk-austin">How To Invest In The City&#8217;s Growth Before He Floods It With New Tech Workers</a>.</li>
<li>Whole Foods&#8217; Landlord Has Achieved A 15% Net IRR For Accredited Investors Since 2015 — <a href="https://www.benzinga.com/go/whole-foods-landlord">Discover The Latest Investment Opportunities On Its Platform</a>.</li>
</ul>
Image Credit: Shutterstock

REIT

Real Estate

CUBE

These Self-Storage REITs Yield Up to 6.3% and Have Track Records of Dividend Growth

Nine months after the U.S. launch of&nbsp;Eisai Limited&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/ESALY#OTC">ESALY</a>) and&nbsp;Biogen Inc&#8217;s&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BIIB#NASDAQ">BIIB</a>) Leqembi, the first drug shown to slow Alzheimer&#8217;s progression, adoption faces hurdles due to skepticism among some doctors.&nbsp;
Initially hopeful, Alzheimer&#8217;s experts anticipated challenges with Leqembi&#8217;s requirements, including frequent infusions and diagnostic tests, leading to slow adoption&nbsp;<a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/23/07/33148410/expanded-medicare-coverage-for-biogen-eisais-leqembi-signals-a-turning-point-in-alz" rel="noreferrer noopener">after FDA approval</a>.&nbsp;
Interviews with 20 neurologists and geriatricians revealed concerns about efficacy, costs, and risks, hampering widespread prescription.
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37897025/european-medicines-agency-delays-approval-decision-for-biogen-eisai-partnered-alzheimers-drug-lec" rel="noreferrer noopener">European Medicines Agency Delays Approval Decision For Biogen-Eisai Partnered Alzheimer&#8217;s Drug Lecanemab</a>.
Reuters highlighted that seven interviewed doctors cited skepticism, while six highlighted &#8220;therapeutic nihilism&#8221; as a significant barrier to Leqembi adoption.&nbsp;
Dr. Reisa Sperling likened skepticism to past fatalistic attitudes toward cancer treatment. Eisai&#8217;s chief administrative officer,&nbsp;Alex Scott, acknowledged skepticism&#8217;s impact, citing historical skepticism toward Alzheimer&#8217;s research.
In trials, Leqembi,&nbsp;targeting&nbsp;amyloid, showed a 27%&nbsp;cognition decline slowdown.&nbsp;However, adoption has been sluggish, with only a fraction of intended patients receiving treatment.&nbsp;
Factors include long adoption cycles for new drugs and concerns about Leqembi&#8217;s efficacy and costs.
Despite FDA approval, less than half of U.S. neurologists recommend Leqembi, citing limited patient benefit and significant risks.&nbsp;
Dr. Michael Greicius doubts Leqembi&#8217;s meaningful patient benefits, given slim trial differences, Reuter writes.&nbsp;Dr. Eric Widera and Donna Fick caution about the drug&#8217;s risks and unclear benefits.
Some physicians have expressed worries regarding the potential for brain swelling and bleeding linked to Leqembi.&nbsp;
They&#8217;ve also highlighted concerns about the financial burden imposed by the drug&#8217;s&nbsp;$26,500&nbsp;yearly cost, along with the expenses related to regular MRIs and bi-monthly infusions.
Reuters notes that of the 10,000 Americans the companies hoped to treat by the end of March, Eisai announced that only a couple thousand had begun treatment as of January.&nbsp;
Biogen and Eisai intend to increase their sales force by 30%, aiming for 100,000 patients by 2026.
In its first-quarter earnings release, Biogen said Leqembi launch uptake accelerated with first-quarter global in-market sales of approximately&nbsp;$19 million, nearly triple the fourth quarter of 2023, and patients on therapy increasing&nbsp;nearly&nbsp;2.5 times&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/04/38410191/biogens-leqembi-commercial-ramp-up-modest-but-up-ticking-reports-mixed-bag-q1-earnings" rel="noreferrer noopener">since the end of 2023</a>.&nbsp;
Read Next:&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/01/36871446/biogen-gives-up-on-aduhelm-efforts-after-two-years-of-controversial-fda-accelerated-approval-for-" rel="noreferrer noopener">Biogen Gives Up On Aduhelm Efforts After Two Years Of Controversial FDA Accelerated Approval For Alzheimer&#8217;s, Shifts Focus On Newer Medicines</a>.
Price Action:&nbsp;BIIB shares are up 3.36% at $199.68&nbsp;at the last check Wednesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photo by Gerd Altmann via Pixabay

Biotech

Large Cap

News

Health Care

Movers

Trading Ideas

General

BIIB

ESALY

Biogen/Eisai's Popular Alzheimer's Drug Leqembi Is Seeing Slow Adoption - Here's Why

Shares of Visa Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/V#NYSE">V</a>) were climbing in early trading on Wednesday, after <a href="https://www.benzinga.com/markets/equities/24/04/38400226/whats-going-on-with-visa-shares-wednesday">the company reported an earnings beat for its fiscal second quarter</a>.
Here are some key analyst takeaways from the release.
<ul>
<li>Goldman Sachs analyst Will Nance reiterated a Buy rating, while raising the price target from $328 to $335.</li>
<li>Oppenheimer analyst Jake Kooyman maintained an Outperform rating, while lifting the price target from $297 to $299.</li>
<li>Wedbush analyst Moshe Katri reaffirmed an Outperform rating, while raising the price target from $280 to $300.</li>
<li>BMO Capital Markets analyst Rufus Hone reiterated an Outperform rating and price target of $300.</li>
<li>Keefe Bruyette &amp; Woods analyst Sanjay Sakhrani maintained an Outperform rating and price target of $325.</li>
<li>Mizuho Securities analyst Dan Dolev reaffirmed a Neutral rating and price target of $265.</li>
</ul>
Check out <a href="https://www.benzinga.com/analyst-stock-ratings">other analyst stock ratings</a>.
Goldman Sachs: Visa reported "solid" quarterly results. Earnings of $2.51 per share beat the consensus of $2.44 per share. The results were driven by "broadly inline trends in revenues aided by a large beat on incentives," Nance said. 
Softer trends in April were seen by the company as "largely a function of Easter timing."
Although management lowered the volume guidance to reflect softer results in the Asia Pacific (APAC) region, they broadly reiterated expectations for improving ticket sizes in both the US and the rest of the world excluding APAC for the rest of the year, "which had been an area of skepticism among investors," the analyst further stated.
Oppenheimer: Visa&#8217;s non-GAAP earnings grew by 20% to $2.51 per share, while net revenue on a constant currency basis rose 10% year-over-year to $8.6 billion, with both figures beating expectations, Kooyman said. 
"Other revenue largely drove the delta versus the Street, which increased 37% year over year driven by strong consulting and marketing services revenue growth," he added.
"Moreover, overall spending trends remained solid, evidenced by an 8% year-over-year increase in payments volume, 11% rise in processed transactions and a 16% gain in constant currency cross-border volume," the analyst wrote. Visa remains on track to generate low double-digit top-line growth and earnings growth in the low teens, he further stated.
Wedbush: Visa reported stronger-than-expected quarterly results and reiterated its full-year guidance, Katri said. Payment volume growth accelerated sequentially by 100 basis points (bps) in the US, but slowed internationally by 100 bps, keeping the aggregate consistent, he added.
"While FY24 guidance was reiterated, management reset expectations for Total volume growth to high single digits from low double digits due to APAC travel slowing recovery," the analyst wrote. "This is being offset by stronger than expected performance in high-yield eCommerce," he further stated.
BMO Capital Markets: Given Visa's "solid" quarterly results, the reiterated revenue guidance for the full year appears "de-risked, supported by accelerating VAS/ New Flows growth, resilient cross-border trends and slower 2H growth in incentive payments," Hone wrote in a note.
"While US payment volume in the first 3 weeks of April are tracking +5% YoY (down slightly from ~6% YoY in March/FY2Q24), Visa noted that the earlier Easter timing this year accounted for the slight sequential deceleration," he added.
Keefe, Bruyette &amp; Woods: Visa reported an earnings beat "driven primarily by client incentives (+$0.10/share), with some added benefit from higher other income (+$0.02/share) and a lower tax rate (+$0.01/share)," Sakhrani said. 
He added, however, that the beat was partially offset by a decline in gross revenues, higher opex, and an increase in share count.
"Visa's results are tracking in-line with expectations, which is a positive relative to intra-quarter concerns that full year targets may prove to be too high," the analyst further stated.
Mizuho Securities: Visa's strong quarterly results "marked by accelerating US volumes (+6% vs. +5%) and unchanged guide should drive a sigh of relief rally in the stock," Dolev said.
Although the company maintaining its full-year revenue guidance is "a key positive," the slower trends in April "can be a potential hurdle" to achieving the same pace of revenue growth in the second half of the year, he added.
V Price Action: Shares of Visa had risen by 0.86% to $276.47 at the time of publication on Wednesday.
Now Read: <a href="https://www.benzinga.com/markets/cryptocurrency/24/04/38412499/treasury-yields-rise-tesla-jumps-on-cheaper-model-pledge-yen-plummets-to-34-year-lows-what">Treasury Yields Rise, Tesla Jumps On Cheaper Model Pledge, Yen Plummets To 34-Year Lows: What&#8217;s Driving Markets Wednesday?</a>

Analyst Color

Earnings Misses

Price Target

Reiteration

Analyst Ratings

Visa Delivers 'Solid' Earnings Beat, 6 Analysts Provide Key Takeaways: 'Blame Easter For Softer Trends'

Citigroup analyst Jason Gursky maintains RTX (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RTX#NYSE">RTX</a>) with a Neutral and raises the price target from $95 to $110.

Citigroup Maintains Neutral on RTX, Raises Price Target to $110

Citigroup analyst Jon Tower maintains Texas Roadhouse (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TXRH#NASDAQ">TXRH</a>) with a Buy and raises the price target from $162 to $178.

TXRH

Citigroup Maintains Buy on Texas Roadhouse, Raises Price Target to $178

Argus Research analyst Stephen Biggar maintains Blackstone (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BX#NYSE">BX</a>) with a Buy and raises the price target from $133 to $135.

Argus Research Maintains Buy on Blackstone, Raises Price Target to $135

Citigroup analyst Ben Gerlinger maintains Webster Finl (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WBS#NYSE">WBS</a>) with a Buy and lowers the price target from $60 to $55.

Citigroup Maintains Buy on Webster Finl, Lowers Price Target to $55

RBC Capital analyst Tom Narayan maintains General Motors (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GM#NYSE">GM</a>) with a Outperform and raises the price target from $56 to $58.

RBC Capital Maintains Outperform on General Motors, Raises Price Target to $58

On Wednesday,&nbsp;Humana&nbsp;Inc&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>), in its first quarter earnings remarks, said the company&nbsp;<a target="_blank" href="https://humana.gcs-web.com/static-files/4a3a2261-3d15-4997-8abc-cec1ed05876d" rel="noreferrer noopener">withdrew</a>&nbsp;its already lowered 2025 profit forecast, citing disappointing government Medicare Advantage (MA)&nbsp;<a target="_blank" href="https://www.benzinga.com/government/24/04/38034935/unitedhealth-humana-cvs-shares-are-sliding-monday-whats-going-on" rel="noreferrer noopener">reimbursement rates</a>.
The insurance firm said the final MA rate notice is&nbsp;not sufficient&nbsp;to address the current medical&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/01/36778837/humana-blames-medicare-advantage-as-stock-falls-after-larger-than-expected-quarterly-loss-grim-outl" rel="noreferrer noopener">cost trend environment</a>.
Humana&#8217;s medical benefit ratio &#8211; the&nbsp;percentage of premiums spent on medical care &#8211; rose to&nbsp;<a target="_blank" href="https://www.benzinga.com/news/earnings/24/04/38405775/humana-boosts-medicare-advantage-membership-2024-forecast-as-q1-earnings-performance-exceeds-expect" rel="noreferrer noopener">88.9% in the first quarter</a>.
In its fourth quarter 2023 earnings release, Humana&nbsp;<a target="_blank" href="https://humana.gcs-web.com/static-files/f601f75a-3e88-4287-a27f-e875be221ad1" rel="noreferrer noopener">said</a>, &#8220;Although we intend to prioritize margin recovery over membership growth in the near term, we no longer believe the previously communicated $37 Adjusted EPS target for 2025 is achievable.&#8221;
&#8220;It is our intent&nbsp;to deliver $6 to $10 of Adjusted EPS growth in 2025 through MA pricing actions, earnings growth in other lines of business, as well as our ongoing productivity and trend mitigation initiatives,&#8221; the company added.
In its first quarter 2024 earnings, the company said: &#8220;Considering the significant difference between the final rate notice and our previous funding assumption, combined with the inherent pricing limitations imposed by the Total Beneficiary Cost (TBC) change thresholds, we no longer believe $6 to $10 of Adjusted EPS growth is the appropriate target range for 2025.&#8221;
Humana said, &#8220;Our 2025 Adjusted EPS growth outlook will&nbsp;be impacted&nbsp;by several variables into which we will not have clear visibility until later this year.&nbsp;As a result, we believe&nbsp;it is prudent to provide&nbsp;more specific guidance for 2025 once we have greater clarity.&#8221;
Humana noted that pricing decisions for the 2025 MA bids are&nbsp;being&nbsp;finalized and will be submitted by the first Monday in June.
The company will provide an update on&nbsp;bid strategy&nbsp;post finalization, with a further update in the Fall once we have visibility into competitor plans and expected membership implications.
Price Action:&nbsp;HUM shares are down 3.75% at $315.68&nbsp;at&nbsp;the last check Wednesday.

Guidance

Tech

Humana Withdraws Its Already Lowered 2025 Profit Guidance

Citigroup analyst Filippo Falorni maintains Kimberly-Clark (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KMB#NYSE">KMB</a>) with a Sell and raises the price target from $111 to $125.

Citigroup Maintains Sell on Kimberly-Clark, Raises Price Target to $125

Citigroup analyst George Kurosawa maintains Manhattan Associates (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MANH#NASDAQ">MANH</a>) with a Neutral and lowers the price target from $260 to $220.

MANH

Citigroup Maintains Neutral on Manhattan Associates, Lowers Price Target to $220

Whales with a lot of money to spend have taken a noticeably bearish stance on Salesforce.
Looking at options history for Salesforce (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CRM#NYSE">CRM</a>) we detected 17 trades.
If we consider the specifics of each trade, it is accurate to state that 41% of the investors opened trades with bullish expectations and 47% with bearish.
From the overall spotted trades, 4 are puts, for a total amount of $295,628 and 13, calls, for a total amount of $888,921.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $200.0 and $410.0 for Salesforce, spanning the last three months.
<h3>Analyzing Volume &amp; Open Interest</h3>
Assessing the volume and open interest is a strategic step in options trading. These metrics shed light on the liquidity and investor interest in Salesforce's options at specified strike prices. The forthcoming data visualizes the fluctuation in volume and open interest for both calls and puts, linked to Salesforce's substantial trades, within a strike price spectrum from $200.0 to $410.0 over the preceding 30 days.
<h3>Salesforce Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713982580_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>03/21/25</td>
<td>$18.15</td>
<td>$18.05</td>
<td>$18.15</td>
<td>$330.00</td>
<td>$168.7K</td>
<td style="text-align: right;">145</td>
<td style="text-align: right;">8</td>
</tr>
<tr>
<td>CRM</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>06/20/25</td>
<td>$45.15</td>
<td>$44.0</td>
<td>$44.0</td>
<td>$300.00</td>
<td>$158.4K</td>
<td style="text-align: right;">397</td>
<td style="text-align: right;">40</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>03/21/25</td>
<td>$67.35</td>
<td>$65.8</td>
<td>$66.5</td>
<td>$230.00</td>
<td>$133.0K</td>
<td style="text-align: right;">16</td>
<td style="text-align: right;">10</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$21.85</td>
<td>$21.65</td>
<td>$21.65</td>
<td>$300.00</td>
<td>$99.5K</td>
<td style="text-align: right;">146</td>
<td style="text-align: right;">64</td>
</tr>
<tr>
<td>CRM</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>03/21/25</td>
<td>$70.95</td>
<td>$68.5</td>
<td>$69.0</td>
<td>$230.00</td>
<td>$69.0K</td>
<td style="text-align: right;">16</td>
<td style="text-align: right;">10</td>
</tr>
</tbody>
</table>

<h3>About Salesforce</h3>
Salesforce Inc provides enterprise cloud computing solutions. The company offers customer relationship management technology that brings companies and customers together. Its Customer 360 platform helps the group to deliver a single source of truth, connecting customer data across systems, apps, and devices to help companies sell, service, market, and conduct commerce. It also offers Service Cloud for customer support, Marketing Cloud for digital marketing campaigns, Commerce Cloud as an e-commerce engine, the Salesforce Platform, which allows enterprises to build applications, and other solutions, such as MuleSoft for data integration.
Following our analysis of the options activities associated with Salesforce, we pivot to a closer look at the company's own performance.
<h3>Where Is Salesforce Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 1,846,367, with CRM's price up by 0.26%, positioned at $277.41.</li>
<li>RSI indicators show the stock to be may be approaching oversold.</li>
<li>Earnings announcement expected in 35 days.</li>
</ul>
<h3>Professional Analyst Ratings for Salesforce</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $351.0.
<ul>
<li>An analyst from Stifel persists with their Buy rating on Salesforce, maintaining a target price of $350. </li>
<li>Reflecting concerns, an analyst from RBC Capital lowers its rating to Outperform with a new price target of $350.</li>
<li>An analyst from Needham downgraded its action to Buy with a price target of $345. </li>
<li>Maintaining their stance, an analyst from Jefferies continues to hold a Buy rating for Salesforce, targeting a price of $360. </li>
<li>In a cautious move, an analyst from RBC Capital downgraded its rating to Outperform, setting a price target of $350. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Salesforce options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

Options

Markets

Looking At Salesforce's Recent Unusual Options Activity

Investors with a lot of money to spend have taken a bullish stance on Mobileye Global (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MBLY#NASDAQ">MBLY</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MBLY, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 9 uncommon options trades for Mobileye Global.
This isn't normal.
The overall sentiment of these big-money traders is split between 44% bullish and 44%, bearish.
Out of all of the special options we uncovered, 3 are puts, for a total amount of $161,832, and 6 are calls, for a total amount of $422,540.
<h3>Expected Price Movements</h3>
Taking into account the Volume and Open Interest on these contracts, it appears that whales have been targeting a price range from $28.0 to $42.0 for Mobileye Global over the last 3 months. 
<h3>Volume &amp; Open Interest Trends</h3>
In terms of liquidity and interest, the mean open interest for Mobileye Global options trades today is 690.43 with a total volume of 1,266.00.
In the following chart, we are able to follow the development of volume and open interest of call and put options for Mobileye Global's big money trades within a strike price range of $28.0 to $42.0 over the last 30 days.
<h3>Mobileye Global 30-Day Option Volume &amp; Interest Snapshot</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713982574_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MBLY</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$2.45</td>
<td>$2.4</td>
<td>$2.4</td>
<td>$31.00</td>
<td>$180.0K</td>
<td>2.2K</td>
<td style="text-align: right;">813</td>
</tr>
<tr>
<td>MBLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$6.9</td>
<td>$6.6</td>
<td>$6.74</td>
<td>$30.00</td>
<td>$120.5K</td>
<td>1.2K</td>
<td style="text-align: right;">179</td>
</tr>
<tr>
<td>MBLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$7.1</td>
<td>$6.9</td>
<td>$7.0</td>
<td>$38.00</td>
<td>$66.5K</td>
<td>35</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>MBLY</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>08/16/24</td>
<td>$11.2</td>
<td>$11.0</td>
<td>$11.0</td>
<td>$42.00</td>
<td>$61.6K</td>
<td>56</td>
<td style="text-align: right;">56</td>
</tr>
<tr>
<td>MBLY</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$6.6</td>
<td>$6.4</td>
<td>$6.53</td>
<td>$29.00</td>
<td>$45.4K</td>
<td>210</td>
<td style="text-align: right;">66</td>
</tr>
</tbody>
</table>

<h3>About Mobileye Global</h3>
Mobileye Global Inc engages in the development and deployment of ADAS and autonomous driving technologies and solutions. It is building a portfolio of end-to-end ADAS and autonomous driving solutions to provide the capabilities needed for the future of autonomous driving, leveraging a comprehensive suite of purpose-built software and hardware technologies. Mobileye is the Company's only reportable operating segment. Its solutions comprise Driver Assist, Cloud-Enhanced Driver Assist, Mobileye SuperVision Lite, Mobileye SuperVision, Mobileye Chauffeur, Mobileye Drive, Self-Driving System &amp; Vehicles. It also provides data services to Expedite Maintenance Operations with AI-Powered Road Survey Technology.
Having examined the options trading patterns of Mobileye Global, our attention now turns directly to the company. This shift allows us to delve into its present market position and performance
<h3>Where Is Mobileye Global Standing Right Now?</h3>
<ul>
<li>With a volume of 1,625,084, the price of MBLY is up 1.48% at $30.88. </li>
<li>RSI indicators hint that the underlying stock is currently neutral between overbought and oversold.</li>
<li>Next earnings are expected to be released in 1 days.</li>
</ul>
<h3>Professional Analyst Ratings for Mobileye Global</h3>
In the last month, 2 experts released ratings on this stock with an average target price of $39.5.
<ul>
<li>Maintaining their stance, an analyst from JP Morgan continues to hold a Overweight rating for Mobileye Global, targeting a price of $38. </li>
<li>In a positive move, an analyst from Wolfe Research has upgraded their rating to Outperform and adjusted the price target to $41. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Mobileye Global options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

MBLY

Spotlight on Mobileye Global: Analyzing the Surge in Options Activity

Financial giants have made a conspicuous bullish move on Lyft. Our analysis of options history for Lyft (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LYFT#NASDAQ">LYFT</a>) revealed 11 unusual trades.
Delving into the details, we found 63% of traders were bullish, while 36% showed bearish tendencies. Out of all the trades we spotted, 4 were puts, with a value of $164,232, and 7 were calls, valued at $1,166,313.
<h3>What's The Price Target?</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $14.0 and $27.0 for Lyft, spanning the last three months.
<h3>Volume &amp; Open Interest Trends</h3>
In today's trading context, the average open interest for options of Lyft stands at 2059.73, with a total volume reaching 1,463.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Lyft, situated within the strike price corridor from $14.0 to $27.0, throughout the last 30 days.
<h3>Lyft Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1713982569_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>LYFT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>07/19/24</td>
<td>$2.2</td>
<td>$2.17</td>
<td>$2.2</td>
<td>$17.00</td>
<td>$770.0K</td>
<td>1.6K</td>
<td style="text-align: right;">23</td>
</tr>
<tr>
<td>LYFT</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/17/24</td>
<td>$2.76</td>
<td>$2.67</td>
<td>$2.67</td>
<td>$14.00</td>
<td>$114.0K</td>
<td>286</td>
<td style="text-align: right;">2</td>
</tr>
<tr>
<td>LYFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>05/03/24</td>
<td>$0.56</td>
<td>$0.37</td>
<td>$0.37</td>
<td>$17.50</td>
<td>$108.6K</td>
<td>4.0K</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>LYFT</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/16/25</td>
<td>$12.05</td>
<td>$11.95</td>
<td>$12.0</td>
<td>$27.00</td>
<td>$73.2K</td>
<td>0</td>
<td style="text-align: right;">3</td>
</tr>
<tr>
<td>LYFT</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>05/17/24</td>
<td>$1.31</td>
<td>$1.28</td>
<td>$1.3</td>
<td>$17.00</td>
<td>$65.0K</td>
<td>2.2K</td>
<td style="text-align: right;">546</td>
</tr>
</tbody>
</table>

<h3>About Lyft</h3>
Lyft is the second-largest ride-sharing service provider in the us and Canada, connecting riders and drivers over the Lyft app. Incorporated in 2013, Lyft offers a variety of rides via private vehicles, including traditional private rides, shared rides, and luxury ones. Besides ride-share, Lyft also has entered the bike- and scooter-share market to bring multimodal transportation options to users.
<h3>Present Market Standing of Lyft</h3>
<ul>
<li>With a volume of 12,069,459, the price of LYFT is down -2.48% at $16.5. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 13 days.</li>
</ul>
<h3>What The Experts Say On Lyft</h3>
Over the past month, 2 industry analysts have shared their insights on this stock, proposing an average target price of $21.0.
<ul>
<li>An analyst from Wells Fargo has decided to maintain their Equal-Weight rating on Lyft, which currently sits at a price target of $18. </li>
<li>An analyst from Tigress Financial persists with their Buy rating on Lyft, maintaining a target price of $24. </li>
</ul>
Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating themselves, adapting their strategies, monitoring multiple indicators, and keeping a close eye on market movements. Stay informed about the latest Lyft options trades with real-time alerts from <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a>.

LYFT

Lyft's Options: A Look at What the Big Money is Thinking

The Senate Committee on Health, Education, Labor, and Pensions is reportedly scrutinizing &nbsp;Novo Nordisk&nbsp;A/S&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>) &#8216;s pricing strategies, particularly those of its diabetes and obesity&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37989566/how-much-does-it-cost-to-make-novo-nordisks-ozempic-shockingly-low-against-1-000-price-tag-study-" rel="noreferrer noopener">medications, Ozempic and Wegovy</a>.
Senator Bernie Sanders emphasized the necessity of reducing prices to ensure accessibility for consumers and sustainability for governments.
Senator Sanders penned a letter to Novo Nordisk&#8217;s CEO, Lars Fruergaard Jorgensen, demanding internal communications regarding the pricing discrepancies between the U.S. and other countries.&nbsp;
The committee questioned why Wegovy, containing the same compound as Ozempic, bears a higher price tag, the New York Times&nbsp;<a target="_blank" href="https://www.nytimes.com/2024/04/24/well/live/ozempic-cost-senate.html?searchResultPosition=1" rel="noreferrer noopener">noted</a>. A response has been requested by May 8.
Senator Sanders also intended to investigate&nbsp;Eli Lilly And Co&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), the manufacturer of rival medications, Mounjaro and Zepbound, to address industry-wide pricing concerns.&nbsp;
With obesity affecting nearly 42% of American adults and over 11 percent with diabetes, ensuring affordability poses a significant challenge.
A recent study by the Kaiser Family Foundation (KFF) revealed that approximately 3.6 million overweight or obese patients with heart conditions covered under the U.S. Medicare program may become eligible for&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/24/03/37984877/insurance-coverage-for-weight-loss-drugs-elevance-cvs-health-become-first-to-extend-coverage-to-n" rel="noreferrer noopener">coverage of Wegovy</a>.&nbsp;
The study highlights that the expanded coverage would affect Medicare beneficiaries and other insurers&#8217; coverage for individuals with heart conditions.&nbsp;
Currently,&nbsp;Medicare prescription drug plans (Part D) administered by private insurers do not cover drugs approved solely for obesity.&nbsp;
However, new guidance suggests that drugs approved for secondary use Medicare covers could be eligible.
Citing the KFF study, Reuters highlights that the approval could open up Wegovy to over a quarter of the 13.7 million Medicare beneficiaries diagnosed with heart disease and obesity.&nbsp;
Among these eligible patients, approximately 1.9 million also have diabetes, making them already eligible for Medicare coverage of other drugs like Novo&#8217;s Ozempic.
Although some Part D plans have announced plans to cover Wegovy this year, broader coverage may be anticipated by 2025.&nbsp;
The extent of the drug&#8217;s coverage and its impact on Medicare spending will depend on various factors. These include the number of Part D plans adding coverage, potential restrictions on use such as prior authorization, and negotiated prices paid by plans.
Despite major insurance plans covering these medications to varying extents, rising costs have led to coverage restrictions and termination, exacerbating accessibility issues.&nbsp;
Medicaid and Medicare coverage disparities further compound the problem.
Price Action:&nbsp;NVO shares are down 1.91% at $126.18&nbsp;at the last check Wednesday.
Disclaimer: This content was partially produced with the help of AI tools and was reviewed and published by Benzinga editors.
Photos courtesy: Shutterstock

Legal

What Are Pricing Strategies for Ozempic And Wegovy With Potential Medicare Coverage Expansion? Senate Committee Questions Novo Nordisk

Citigroup analyst Patrick Donnelly maintains Danaher (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DHR#NYSE">DHR</a>) with a Buy and raises the price target from $280 to $290.

Citigroup Maintains Buy on Danaher, Raises Price Target to $290

Heineken NV&nbsp;(OTC:<a class="ticker" href="https://www.benzinga.com/stock/HEINY#OTC">HEINY</a>) clocked&nbsp;revenue&nbsp;<a target="_blank" href="https://www.heinekenholding.com/investors/media-releases/heineken-holding-nv-reports-2024-first-quarter-trading" rel="noreferrer noopener">growth&nbsp;</a>of 7.2% Y/Y in the first quarter of FY24 to 8.18 billion euros, driven by volume growth of 4.3% Y/Y and net revenue (beia) per hectolitre increase of&nbsp;4.9% Y/Y.
Beer volume increased 4.7% organically Y/Y on growth across all regions, a sequential improvement in the performance of the business, boosted by calendar and one-off effects.&nbsp;
Beer volume came ahead of the company-provided market expectations of 2.5%,&nbsp;reported&nbsp;WSJ.
In particular, the Americas and Europe regions benefitted from the earlier timing of Easter&nbsp;and&nbsp;the Africa &amp; Middle East.
Also, the&nbsp;Asia Pacific regions gained from a soft comparable base last year due to one-off effects in Vietnam and Nigeria.
Also Read:&nbsp;<a target="_blank" href="https://www.benzinga.com/markets/equities/23/08/34039199/cheers-to-no-cheers-heineken-closes-russian-operations-takes-300m-loss" rel="noreferrer noopener">Cheers To No Cheers: Heineken Closes Russian Operations, Takes €300M&nbsp;Loss</a>
Outlook: The company continues to expect FY24 operating&nbsp;profit (beia) to grow organically by a low- to high-single-digit and net profit (beia) organic growth to be lower than the operating profit (beia) organic growth.
Price Action: HEINY shares were trading higher by 1.39% at $49.71 at the last check Wednesday.
Photo: Engin Akyurt from Pixabay

Earnings

Equities

Media

HEINY

Heineken's Cheers: A Round of 7.2% Revenue Growth in Q1

Citigroup analyst James Hardiman maintains Mattel (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAT#NASDAQ">MAT</a>) with a Buy and raises the price target from $25 to $26.

Citigroup Maintains Buy on Mattel, Raises Price Target to $26

WIIM

Boeing shares are trading lower after Moody's downgraded the company's Senior Unsecured rating from Baa2 to Baa3.

Citigroup analyst Patrick Donnelly maintains Quest Diagnostics (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DGX#NYSE">DGX</a>) with a Neutral and raises the price target from $135 to $145.

Citigroup Maintains Neutral on Quest Diagnostics, Raises Price Target to $145

Earnings Unlikely To Spoil Stock Rally

Active Management Insights: To Tech And Beyond?

Can The 'Magnificent Seven' Tech Giants Continue To Outperform Following Impressive Quarterly Results

Tech Was Best In Q4 Earnings But Look To The Rest As Market Broadens

Taking Stock: Q2 2024 Equity Market Outlook

First Trust Expanded Technology ETF declares $0.0061 dividend

Equity Outlook: Earnings Step Back Into The Market Spotlight

April 2024 Perspective

Tailwinds In Tech

The Outlook For The U.S. Economy Is Bullish

AAPL

ACES

ACTV

ACWI

ACWV

AFMC

AFSM

AFTY

AGNG

AIRR

AMZN

ANEW

ARKF

ARKG

ARKK

ARKQ

ARKW

ARKX

ASET

ASHR

ASHS

ASHX

AVEM

AVES

AVUV

BAPR

BBEU

BBJP

BBMC

BFOR

BKMC

BLCN

BLOK

BMED

BMVP

BOTZ

BOUT

BTEC

BTEK

CBON

CCRV

CHIC

CHIE

CHIH

CHII

CHIK

CHIM

CHIQ

CHIR

CHIS

CHIU

CHIX

CIBR

CLOU

CMDY

CNCR

CNRG

CNXT

CNYA

COMB

COMT

CQQQ

CRBN

CTEC

CXSE

DAPP

DBEM

DBEU

DBEZ

DBJP

DDIV

DEUS

DFEV

DGRO

DIEM

DJCB

DRIV

DTEC

DVLU

DWLD

DXJS

ECNS

EDOC

EJUL

EMCR

EMFM

EMXC

EQAL

ERTH

ESGE

ESGG

ESPO

ETHO

EUDG

EUDV

EURL

EUSC

EWJV

FAAR

FCOM

FEUZ

FFTY

FHLC

FIDU

FINX

FITE

FIVG

FLCH

FLEE

FLEU

FLHK

FLJH

FLJP

FLQM

FLTW

FNDB

FNDX